Deal Tracker · Countries

Taiwan pharma deals

4 pharma deals involving Taiwan — companies based there or deals covering the market — tracked by EPT: licensing, distribution & M&A. Most active: Lotus Pharmaceutical, ADCAN Pharma, Duopharma Biotech & Enimmune. Latest: Enimmune → Duopharma Biotech (Distribution, 15 Oct 2026).

4
deals tracked
11
countries involved
—
values undisclosed
50%
licensing, the top deal type
  • EPT has tracked 4 Taiwan pharma deals (2026).
  • The most common structures are licensing (50%), distribution (25%) & m&a (25%).
  • None of these deals disclosed a value, which is common for licensing and distribution agreements in these markets.
  • The most active companies: Lotus Pharmaceutical (2).

Most active companies

Lotus Pharmaceutical (2)

Countries involved

Malaysia (2) · Philippines (2) · Indonesia (1) · Iraq (1) · Japan (1) · Libya (1)

Questions

How many Taiwan pharma deals has EPT tracked?
4 as of 15 Oct 2026, covering 2026. The most recent is Enimmune → Duopharma Biotech (Distribution, 15 Oct 2026).
What types of Taiwan pharma deals are most common?
Licensing: 2 (50%); Distribution: 1 (25%); M&A / Acquisition: 1 (25%).
Which companies are most active in Taiwan pharma deals?
Lotus Pharmaceutical (2 deals).

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)